Form 4: AnaptysBio CEO Daniel Faga Acquires 160,000 Performance Stock Units

AnaptysBio's CEO, Daniel Faga, acquired 160,000 performance stock units (PSUs) on July 22, 2024, contingent upon achieving certain share price metrics.

Summary

• On July 22, 2024, Daniel Faga, CEO of AnaptysBio, acquired 160,000 performance stock units (PSUs).
• Each PSU represents a contingent right to receive one share of AnaptysBio's common stock upon settlement, with no consideration required.
• The PSUs vest upon the achievement of certain share price metrics.
• 50% of the shares subject to the PSU that achieves the applicable performance metrics will vest on the later of (i) the 1-year anniversary of the achievement of such applicable Performance Metrics and (ii) on July 1, 2026.
• An additional 50% of the shares will vest on the 2-year anniversary of such achievement, but not later than July 1, 2028, subject to the Reporting Person' service to the Issue on each vesting date.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, aligning management interests with shareholder value through performance-based incentives. This is generally viewed positively.

Positives

• The acquisition of PSUs by the CEO aligns his interests with those of the shareholders, as the PSUs vest only upon achieving certain share price metrics.
• The vesting schedule incentivizes long-term performance and commitment from the CEO.

Risks

• The vesting of the PSUs is contingent on achieving specific share price metrics, which may not be met.
• The continued service requirement for vesting introduces the risk of forfeiture if the CEO leaves the company before the vesting dates.

Future Outlook

The vesting of the PSUs is tied to the future performance of AnaptysBio's share price, incentivizing management to drive shareholder value.

Industry Context

This type of equity compensation is common in the biotech industry to align executive incentives with company performance and shareholder returns. It is a standard practice to motivate key executives.

Comparison to Industry Standards

• Many biotech companies use performance-based equity awards to incentivize executives.
• Companies like Amgen, Regeneron, and Gilead Sciences also utilize similar performance-based compensation structures.
• The specific metrics and vesting schedules vary, but the underlying principle of aligning executive compensation with shareholder value is consistent across the industry.

Stakeholder Impact

• Shareholders may view the PSU grant positively as it aligns the CEO's interests with increasing shareholder value.
• Employees may see this as a positive sign of the company's commitment to incentivizing leadership.

Key Dates